Global Bacteriophages Therapy Market - 2024-2031

Global Bacteriophages Therapy Market - 2024-2031

Global Bacteriophages Therapy market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

The use of bacteriophages therapeutically to treat pathogenic bacterial illnesses is known as phage therapy. The bacterial infection is stopped when the bacteria produce the viral genome, which impedes the virus's capacity to function. The infection-causing bacterial cell cannot proliferate and instead creates more phages.

Benefits include a lower chance of adverse effects and bacterial resistance because bacteriophages are far more selective than antibiotics. Since they usually pose little threat to the host organism and other helpful bacteria like the gut microbiota, the likelihood of opportunistic infections is decreased.

Market Dynamics: Drivers & Restraints

Increase in the incidence of infectious diseases

The increase in the prevalence of infectious diseases is expected to drive market growth in the forecast period. Conventional therapies lose their efficacy when germs grow resistant to widely used antibiotics, which raises the expense of healthcare, lengthens hospital stays, and increases fatality rates. Bacteriophage therapy helps in treating the infectious diseases.

According to the World Health Organization in 2023, around 1,80,000 deaths occurred due to burns and their infection due to pathogenic organisms can increase the complexity of the wound conditions. The majority of these occur in low- and middle-income countries and almost two-thirds occur in the WHO African and South-East Asia Regions.

Additionally, according to NIH in 2023, chronic rhinosinusitis is one of the most common chronic diseases that develop as a result of the inflammatory process of the paranasal sinuses. The prevalence of chronic rhinosinusitis ranges from 2% to 16% and is more common in patients aged 18-64 years. Thus, the above factors are expected to drive the market growth.

High cost of development and production

It takes time and effort to isolate, characterize, and optimize certain bacteriophages for target bacteria to develop and produce phage therapy products. This can be a time-consuming and costly procedure that calls for specific knowledge and resources. Smaller businesses find it difficult to get into the market due to the high expense of clinical studies and regulatory constraints. Thus, high costs can hamper the market growth.

Segment Analysisn

The global bacteriophage therapy market is segmented based on product, route of administration, targeted bacteria, disease indication, end user and region.

The urinary tract infections segment is expected to dominate the market share

The urinary tract infections segment is expected to hold the dominant position in the market growth due to the increase in the prevalence of infections in individuals. For instance, according to the Urology Care Foundation in 2023, It is estimated that around 8 million individuals visit hospitals every year due to Urinary Tract Infections (UTIs).

UTIs are the second most common type of infection in the body. About 10 in 25 women and 3 in 25 men will have symptoms of a UTI during their lifetime. Around 2.5% of all children will get a UTI. UTIs are most common in children under the age of 5 years. Girls are more likely than boys to get a UTI. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the bacteriophages therapy market share

North America is expected to hold a dominant position in the market growth. This is due to the research and development that is being carried out at several top research institutes and academic centers in North America. This strengthens the body of knowledge and makes it easier for scientists and physicians to work together.

The availability of well-known biotechnology and pharmaceutical companies that are adept at developing and marketing cutting-edge therapies is largely responsible for the availability of phage therapy products.

For instance, in May 2023, the University of Leicester formally opened a state-of-the-art research laboratory dedicated to studying bacteriophages as a means of fighting antibiotic-resistant bacteria. The UK's first of its kind, the Centre for Phage Research will investigate phage-based treatments for bacterial illnesses as an alternative to antibiotics. Thus, the above factors are expected to drive the market growth in the region during the forecast period.

COVID-19 Impact Analysis

COVID-19 has had a negative impact on the market growth. This is due to the shift of research and development activities directed to COVID-19 research, which has slowed down the field's advancement. The pandemic led to resource shortages and economic upheavals that could have affected phage treatment research and development financing. The attention to COVID-19 has caused regulatory procedures to be delayed, which might have hampered the approval of phage treatment products.

Market Segmentation

By Product
• Phage Cocktails
• Phage sprays
• Phage Tablets & Capsules
• Others

By Route of Administration
• Oral
• Topical
• Parenteral

By Targeted Bacteria
• Staphylococci
• Streptococci
• Escherichia coli
• Other Bacterial Pathogens

By Disease Indication
• Urinary Tract Infections
• Infected Burn Wounds
• Chronic Otitis
• Chronic Venous Leg Ulcers
• Chronic Rhinosinusitis

By End-User
• Hospitals & Clinics
• Specialty Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Eliava Biopreparation LLC, BiomX Ltd., Phi Therapeutics, TechnoPhage SA, Intralytix, Inc., Locus Biosciences, Inc., Eligo Bioscience, Armata Pharmaceuticals, Inc. among others.

Why Purchase the Report?
• To visualize the global bacteriophages therapy market segmentation based on product, route of administration, targeted bacteria, disease indication, end user and region as well as understand key commercial assets and players.
• identify commercial opportunities by analyzing trends and co-development.
• excel data sheet with numerous data points of the bacteriophages therapy market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global bacteriophages therapy market report would provide approximately 55 tables, 58 figures and 180 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies